Mission Statement

Advanced Genomic Technology, LLC (AGT) is a biotechnology company based in Louisville, Kentucky, founded in December 2005. AGT’s mission is to develop and market a non-invasive, blood-based test for diagnosis and prognosis of: Alzheimer’s disease (AD) victims and at-risk groups, including individuals with mild cognitive impairment (MCI) and elderly > 65 years of age;

and (2.) metastatic ovarian cancer (ova-ca), providing RNA-based early detection for restricted metastatic carcinoma. The success of this mission will generate medical diagnostic tests characterized by:

 

  •  Accurate, non-invasive approach based on peripheral blood and serum/plasma 
  •  High-throughput quantitative diagnostic and prognostic assessment of AD and ovarian cancer 
  •  Applicable as efficacy tests for new anti-AD and anti-metastatic ovarian carcinoma drugs
  •  Useful for risk assessment of MCI individuals to develop full-blown AD
  •  A combinatoric approach with MRI imaging for metastatic ova-ca as pre-surgical testing

 

AGT aims to penetrate the healthcare market of AD and ovarian cancer with highly accurate, non-invasive, inexpensive, blood-based medical diagnostic/prognostic tests, enabling diagnosis for not only AD and ovarian cancer victims but also those at risk for these diseases. AGT’s core technology for AD diagnosis is based on microRNA expression in peripheral blood mononuclear cells (PBMC) and serum/plasma. The major component of non-coding RNA is various microRNAs, acting as genetic ‘dimmer switches’ to negatively regulate their target genes’ expression. Emerging results show that microRNAs are potential candidates in the etiology of many diseases, from cancer to cardio- and neuro-degeneration; AGT has already applied this technology to the diagnosis of Alzheimer’s disease, and will apply it further to detect its presence in the diagnosis of ovarian cancer patient serum. Changes in expression levels of the lead microRNAs identified in PBMC and/or serum will serve as diagnostics in a cost-effective Point-of-Care process, rendering the most affordable large-scale diagnostic and prognostic tests, not available in the current clinical diagnosis market.